Acute Kidney InjuryVEMhemodiAKINCT07637435
Role of Vascular Endothelial Markers in Predicting Renal Prognosis and Mortality in Patients Undergoing HD-AKI
A study testing Serum samples before hemodialysis. in people with Acute Kidney Injury and Hemodialysis, run by Muğla Sıtkı Koçman University at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study was to evaluate the role of Activin A, Nostrin, and Angiopoetin-2 levels in predicting the prognosis of renal function and in-hospital and 6-month mortality in patients undergoing emergency hemodialysis treatment for acute kidney injury. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Kidney Injury, Hemodialysis
- What is being tested?
- Serum samples before hemodialysis.
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 170 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 21 Feb 2025to 15 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients 18 years and older of age requiring hemodialysis for acute kidney injury
Who cannot join
- Patients under 18 years of age
- Patients under chronic renal replacement therapy
- Patients with a history of renal transplantation
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Mugla Sitki Kocman University
Muğla, Menteşe, 48000
About this study
Official title: The Role of Vascular Endothelial Markers in Predicting Renal Function Prognosis and Mortality in Patients Undergoing Emergency Hemodialysis Due to Acute Kidney Injury
The aim of this study was to evaluate the role of Activin A, Nostrin, and Angiopoetin-2 levels in predicting the prognosis of renal function and in-hospital and 6-month mortality in patients undergoing emergency hemodialysis treatment for acute kidney injury. The main questions it aims to answer are:
Acute renal injury is a clinical entity with very important consequences. Mortality and morbidity are high in patients requiring hemodialysis. This study aims to evaluate the predictive effects of certain biomarkers on outcomes such as short- and long-term monitoring of renal function, weaning or continuation of hemodialysis, in-hospital and 6-month mortality in these patients. In patients with an indication for emergency hemodialysis, the following levels will be measured before hemodialysis:
- Serum Activin A,
- Serum Nostrin,
- Serum Angiopoetin-2
Read the detailed description
In this single-center study, the investigators evaluated patients diagnosed with acute kidney injury (AKI) who underwent emergency hemodialysis. AKI has a high mortality rate and can be accompanied by many complications. Progression to chronic kidney disease is one of the most important of these complications. Identifying prognostic determinants in patients receiving hemodialysis treatment due to AKI can provide significant benefits for clinical practice. In this study, the investigators aimed to determine the prognosis in this patient group using some vascular-endothelial markers. The investigators collected serum samples before hemodialysis from AKI patients indicated for hemodialysis and measured the levels of Activin A, Nostrin, and Angiopoetin-2. The investigators aimed to evaluate the relationship between these levels and parameters such as in-hospital mortality, 6-month mortality, and weaning from hemodialysis after 6 months or hemodialysis dependence.
- Conditions
- Acute Kidney Injury, Hemodialysis
- Being tested
- Serum samples before hemodialysis.
- Keywords
- Activin A, Nostrin, Angiopoetin-2, Acute kidney injury, Hemodialysis
- Medical subject headings
- Acute Kidney Injury
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Serum samples before hemodialysis.Diagnostic test
Except from taking a venous blood sample there are no interventions.
| Study group | Role | What they receive |
|---|---|---|
| AKI-HD GROUP | Other | Acute kidney injury (undergoing hemodialysis) arm. The only group in the study. Measurement of serum Activin A, serum Nostrin, serum Angiopoetin-2 Receives: Diagnostic Test: Serum samples before hemodialysis. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation of serum nostrin, activin A, angiopoetin-2 levels and in-hospital clinical results and outcomes (mortality, weaning from HD)
Up to 3 months were sufficient for patient recruitment for the study. After patient recruitment was completed, the investigators followed the patients during their in-hospital days monitoring their need for hemodialysis and survival/death status.
Measured: From the day of the first hemodialysis session until in-hospital death or discharge. (maximum up to 100 days)
Secondary outcomes (1)
All cause mortality and need for hemodialysis or weaning from hemodialysis
Patients who were discharged from the hospital after the initiation of hemodialysis were followed up for 180 days in terms of discontinuing or continuing hemodialysis treatment and survival/death status.
Measured: 180 days after the initiation of first hemodialysis session
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jun 2026
- Study start21 Feb 2025
- Primary completion15 May 2025
- Study completion15 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Acute Kidney InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 170 participants (actual)
Sponsor and investigators
- Lead sponsor
- Muğla Sıtkı Koçman University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alper Alp, Muğla Sıtkı Koçman University
- Investigators
- Alper Alp, Assoc Prof,MD, Principal investigator, Muğla Sıtkı Koçman University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07637435
- Sponsor's protocol ID
- 25/22
- Acronym
- VEMhemodiAKI
- Status last verified
- Jun 2026
- First submitted
- 7 May 2026
- Last updated
- 11 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is no plan to share individual data from this study.
Publications
Erfurt S, Lauxmann M, Asmus K, Oess S, Patschan D, Hoffmeister M. Serum Nostrin-A risk factor of death, kidney replacement therapy and acute kidney disease in acute kidney injury. PLoS One. 2024 Apr 11;19(4):e0299131. doi: 10.1371/journal.pone.0299131. eCollection 2024.
PubMed 38603667Kovacevic I, Hu J, Siehoff-Icking A, Opitz N, Griffin A, Perkins AC, Munn AL, Muller-Esterl W, Popp R, Fleming I, Jungblut B, Hoffmeister M, Oess S. The F-BAR protein NOSTRIN participates in FGF signal transduction and vascular development. EMBO J. 2012 Aug 1;31(15):3309-22. doi: 10.1038/emboj.2012.176. Epub 2012 Jun 29.
PubMed 22751148Robinson-Cohen C, Katz R, Price BL, Harju-Baker S, Mikacenic C, Himmelfarb J, Liles WC, Wurfel MM. Association of markers of endothelial dysregulation Ang1 and Ang2 with acute kidney injury in critically ill patients. Crit Care. 2016 Jul 3;20(1):207. doi: 10.1186/s13054-016-1385-3.
PubMed 27372077
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of Vascular Endothelial Markers in Predicting Renal Function Prognosis and Mortality in Patients Undergoing Emergency Hemodialysis Due to Acute Kidney Injury
- ClinicalTrials.gov ID
- NCT07637435
- Acronym / sponsor ID
- VEMhemodiAKI / 25/22
- Conditions
- Acute Kidney Injury, Hemodialysis
- Keywords
- Activin A, Nostrin, Angiopoetin-2, Acute kidney injury, Hemodialysis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 170 participants (actual)
- Lead sponsor
- Muğla Sıtkı Koçman UniversityUniversity, hospital or other
- Study start
- 21 Feb 2025 (actual)
- Primary completion
- 15 May 2025 (actual)
- Study completion
- 15 Dec 2025 (actual)
- First posted
- 9 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study was to evaluate the role of Activin A, Nostrin, and Angiopoetin-2 levels in predicting the prognosis of renal function and in-hospital and 6-month mortality in patients undergoing emergency hemodialysis treatment for acute kidney injury. The main questions it aims to answer are:
Acute renal injury is a clinical entity with very important consequences. Mortality and morbidity are high in patients requiring hemodialysis. This study aims to evaluate the predictive effects of certain biomarkers on outcomes such as short- and long-term monitoring of renal function, weaning or continuation of hemodialysis, in-hospital and 6-month mortality in these patients. In patients with an indication for emergency hemodialysis, the following levels will be measured before hemodialysis:
- Serum Activin A,
- Serum Nostrin,
- Serum Angiopoetin-2
Detailed description
In this single-center study, the investigators evaluated patients diagnosed with acute kidney injury (AKI) who underwent emergency hemodialysis. AKI has a high mortality rate and can be accompanied by many complications. Progression to chronic kidney disease is one of the most important of these complications. Identifying prognostic determinants in patients receiving hemodialysis treatment due to AKI can provide significant benefits for clinical practice. In this study, the investigators aimed to determine the prognosis in this patient group using some vascular-endothelial markers. The investigators collected serum samples before hemodialysis from AKI patients indicated for hemodialysis and measured the levels of Activin A, Nostrin, and Angiopoetin-2. The investigators aimed to evaluate the relationship between these levels and parameters such as in-hospital mortality, 6-month mortality, and weaning from hemodialysis after 6 months or hemodialysis dependence.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| AKI-HD GROUP | Other | Diagnostic Test: Serum samples before hemodialysis.Acute kidney injury (undergoing hemodialysis) arm. The only group in the study. Measurement of serum Activin A, serum Nostrin, serum Angiopoetin-2 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients 18 years and older of age requiring hemodialysis for acute kidney injury
Key exclusion criteria (3 listed)
- Patients under 18 years of age
- Patients under chronic renal replacement therapy
- Patients with a history of renal transplantation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Serum samples before hemodialysis.Except from taking a venous blood sample there are no interventions. | Diagnostic test | AKI-HD GROUP |
Primary outcome
Correlation of serum nostrin, activin A, angiopoetin-2 levels and in-hospital clinical results and outcomes (mortality, weaning from HD)
Time frame: From the day of the first hemodialysis session until in-hospital death or discharge. (maximum up to 100 days)
Up to 3 months were sufficient for patient recruitment for the study. After patient recruitment was completed, the investigators followed the patients during their in-hospital days monitoring their need for hemodialysis and survival/death status.
1 secondary outcome
All cause mortality and need for hemodialysis or weaning from hemodialysis
Time frame: 180 days after the initiation of first hemodialysis session
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2026.
- Background: PubMed 38603667Erfurt S, Lauxmann M, Asmus K, Oess S, Patschan D, Hoffmeister M. Serum Nostrin-A risk factor of death, kidney replacement therapy and acute kidney disease in acute kidney injury. PLoS One. 2024 Apr 11;19(4):e0299131. doi: 10.1371/journal.pone.0299131. eCollection 2024.
- Background: PubMed 22751148Kovacevic I, Hu J, Siehoff-Icking A, Opitz N, Griffin A, Perkins AC, Munn AL, Muller-Esterl W, Popp R, Fleming I, Jungblut B, Hoffmeister M, Oess S. The F-BAR protein NOSTRIN participates in FGF signal transduction and vascular development. EMBO J. 2012 Aug 1;31(15):3309-22. doi: 10.1038/emboj.2012.176. Epub 2012 Jun 29.
- Background: PubMed 27372077Robinson-Cohen C, Katz R, Price BL, Harju-Baker S, Mikacenic C, Himmelfarb J, Liles WC, Wurfel MM. Association of markers of endothelial dysregulation Ang1 and Ang2 with acute kidney injury in critically ill patients. Crit Care. 2016 Jul 3;20(1):207. doi: 10.1186/s13054-016-1385-3.
- Individual participant dataSharing planned: No. There is no plan to share individual data from this study.
Related trials for Acute Kidney Injury
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery
Renal Injury, Acute Kidney Injury
Recruiting
Acute Kidney Injury and Ultra-endurance Running
AKI (Acute Kidney Injury) Due to Trauma
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Not yet recruitingObservational study
Diastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy
Acute Kidney Injury, Hypotension (MeSH: D007022)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alper Alp, Assoc Prof,MD principal investigator
Muğla Sıtkı Koçman University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Serum samples before hemodialysis. in people with Acute Kidney Injury and Hemodialysis, run by Muğla Sıtkı Koçman University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation of serum nostrin, activin A, angiopoetin-2 levels and in-hospital clinical results and outcomes (mortality, weaning from HD) (time frame: From the day of the first hemodialysis session until in-hospital death or discharge. (maximum up to 100 days)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07637435, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2026.